+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
MALE
ID06990880

Evaluation of GSK5458514 Alone or With Other Anti-Cancer Agents in Adult Men with Metastatic Castration-Resistant Prostate Cancer An Open-Label, First-Time-in-Human Dose Escalation and Expansion Study

Led by GlaxoSmithKline · Updated on 2026-10-05

85

Participants Needed

20

Research Sites

41 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and how the body processes the study drug GSK5458514 in adult male participants with metastatic castration-resistant prostate cancer mCRPC. This Phase 12 study is a first-time-in-human, open-label trial conducted in multiple centers. It includes participants who have confirmed prostate adenocarcinoma with metastatic disease and have experienced treatment failures with previous anti-androgen and chemotherapy therapies. The study has two parts Part 1 is a dose escalation phase where participants receive increasing doses of GSK5458514 alone, and Part 2 is a dose expansion phase where the drug is further evaluated at selected doses. Participants will receive GSK5458514 either alone or in combination with other anti-cancer agents. The treatment period includes monitoring for dose-limiting toxicities and adverse events, with follow-up lasting up to approximately 29 to 32 months for various safety and pharmacokinetic assessments. Participants will undergo multiple assessments including tumor biopsies for biomarker analysis, imaging scans to confirm disease progression, and blood tests to monitor drug levels and immune responses. Researchers will track adverse events, dose modifications, and responses such as prostate-specific antigen decreases and tumor response rates. Safety monitoring and follow-up visits will continue for up to nearly three years to evaluate the drugs effects and participant health throughout the study.

CONDITIONS

Brief Title

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

Research Team

U

US GSK Clinical Trials Call Center

E

EU GSK Clinical Trials Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here